Inhibiting CREB binding protein (CBP)
US11254674B2 · kind B2 · utility
1Cited by
6References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 8, 2020 |
| Grant date | Feb 22, 2022 |
| Priority date | — |
| Expiry date | Jun 8, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.